|
Hologic is submitting this report in accordance with 21.Cfr part 803.The submission is based upon the currently available information.The submission of this report does not represent a confirmation of device malfunction involving the hologic products in the event described.A device history record (dhr) review was conducted for the reported lot/serial number.The device was released meeting all qa specifications.The device involved in this event was not returned for evaluation purposes; therefore, visual and functional analysis of the product could not be performed.We are unable to confirm a relationship between the device and the issue reported.The information obtained during complaint investigation will be included in our global complaint trending and product surveillance will continue to monitor complaints of this type for adverse trends.If the product is received or additional information is obtained, the investigation will be reopened accordingly per standard operating procedure.
|
|
It was reported that a patient received a biozorb device on (b)(6) 2019, after a lumpectomy.Multiple lesions were removed during surgery and axillary and sternum and neck were deemed positive.The patient was reported to receive chemotherapy (perjecta, caroplatin, herceptin, toxotere, and the patient had a complete response to chemo).The patient reported that she experienced pain due to the biozorb device.Additionally, the patient reported that she believes that it was affecting her white blood cell count, and that the chemotherapy was affecting her muscle mass.The patient also reported that she experienced allergic reactions and treatment for infection at the wound site.On (b)(6) 2020, the biozorb was removed with all metallic markers.
|